Immutep Limited announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patients into the trial. Immutep expects to report further data from TACTI-002 at a scientific conference in calendar year 2021 or early calendar year 2022. Patient recruitment is now complete for Parts B and C of TACTI-002 and continues to progress well for the expansion stage of Part A. A total of 154 patients out of up to 183 are now participating in TACTI- 002 at currently 19 clinical sites across Australia, Europe, the UK and US. The data presented for 2nd line PD-1/PD-L1 resistant NSCLC at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting as part of a late breaker poster looked encouraging, especially when compared to alternative treatment options. Based on the data, the DMC confirmed a positive risk-benefit-ratio in this very difficult to treat patient population with confirmed progression (i.e. two consecutive scans) and often low PD-L1 expression levels and recommended the opening of Stage 2 of this part in March 2021.